 Connection
Navin Pinto to N-Myc Proto-Oncogene Protein
This is a "connection" page, showing publications Navin Pinto has written about N-Myc Proto-Oncogene Protein.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.576 |
|
|
|
-
Taylor MR, Anderson JR, Park JR, Irwin MS, Applebaum MA, Pinto NR, Streby K, Federico SM, Rosswog C, Ohira M, Kao PC, London WB, Cash T. Outcomes for Patients Aged 12-18 Months With Metastatic MYCN Non-Amplified Neuroblastoma and Unfavorable Biologic Features ("Mixed Biology Toddlers"): A Report From the International Neuroblastoma Risk Group (INRG) Project. Pediatr Blood Cancer. 2025 Nov; 72(11):e31968.
Score: 0.231
-
Pinto N, Naranjo A, Ding X, Zhang FF, Hibbitts E, Kennedy R, Tibbetts R, Wong-Michalak S, Craig DW, Manojlovic Z, Hogarty MD, Kreissman S, Bagatell R, Irwin MS, Park JR, Asgharzadeh S. Impact of Genomic and Clinical Factors on Outcome of Children =18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report. Clin Cancer Res. 2023 04 14; 29(8):1546-1556.
Score: 0.196
-
Pinto N, Naranjo A, Hibbitts E, Kreissman SG, Granger MM, Irwin MS, Bagatell R, London WB, Greengard EG, Park JR, DuBois SG. Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG). Eur J Cancer. 2019 05; 112:66-79.
Score: 0.148
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|